Cargando…

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease

In the absence of an approved vaccine, developing effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals is essential to tackle the current pandemic health crisis due to the coronavirus disease 2019 (COVID-19) spread. As any traditional drug discovery program is a time-con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delre, Pietro, Caporuscio, Fabiana, Saviano, Michele, Mangiatordi, Giuseppe Felice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701290/ https://www.ncbi.nlm.nih.gov/pubmed/33304884 http://dx.doi.org/10.3389/fchem.2020.594009

Ejemplares similares

Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
por: Osipiuk, Jerzy, et al.
Publicado: (2021)

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022)

Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
por: Hognon, Cécilia, et al.
Publicado: (2022)

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022)

Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
por: Sanders, Brian C., et al.
Publicado: (2023)

Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
por: Weglarz-Tomczak, Ewelina, et al.
Publicado: (2021)

A covalent inhibitor targeting the papain-like protease from SARS-CoV-2 inhibits viral replication
por: Han, Hesong, et al.
Publicado: (2023)

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
por: Wang, Qian, et al.
Publicado: (2023)

Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease: Parthenolide covalently inhibits papain-like protease
por: Zou, Zhihui, et al.
Publicado: (2022)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication
por: Bajaj, Teena, et al.
Publicado: (2023)

A Comparative Molecular Dynamics Study of Selected Point Mutations in the Shwachman–Bodian–Diamond Syndrome Protein SBDS
por: Spinetti, Elena, et al.
Publicado: (2022)

More Is Always Better Than One: The N-Terminal Domain of the Spike Protein as Another Emerging Target for Hampering the SARS-CoV-2 Attachment to Host Cells
por: Di Gaetano, Sonia, et al.
Publicado: (2021)

Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study
por: Creanza, Teresa Maria, et al.
Publicado: (2021)

GENERA: A Combined Genetic/Deep-Learning Algorithm for Multiobjective Target-Oriented De Novo Design
por: Lamanna, Giuseppe, et al.
Publicado: (2023)

Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease
por: Pinzi, Luca, et al.
Publicado: (2021)

Boroleucine‐Derived Covalent Inhibitors of the ZIKV Protease
por: Braun, Niklas J., et al.
Publicado: (2022)

Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs
por: Kouznetsova, Valentina L., et al.
Publicado: (2020)

Ligand-based prediction of hERG-mediated cardiotoxicity based on the integration of different machine learning techniques
por: Delre, Pietro, et al.
Publicado: (2022)

Endocannabinoid Degradation Enzyme Inhibitors as Potential Antipsychotics: A Medicinal Chemistry Perspective
por: Mangiatordi, Giuseppe Felice, et al.
Publicado: (2023)

In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
por: Huynh, Tien, et al.
Publicado: (2021)

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors
por: Ma, Chunlong, et al.
Publicado: (2022)

Inhibitor induced conformational changes in SARS-COV-2 papain-like protease
por: Ferreira, Glaucio Monteiro, et al.
Publicado: (2022)

Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease
por: Xu, Yunxia, et al.
Publicado: (2021)

Repurposing the McoTI-II Rigid Molecular Scaffold in to Inhibitor of ‘Papain Superfamily’ Cysteine Proteases
por: Mishra, Manasi, et al.
Publicado: (2020)

Identification of covalent active site inhibitors of dengue virus protease
por: Koh-Stenta, Xiaoying, et al.
Publicado: (2015)

Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?
por: Maiti, Biplab K
Publicado: (2020)

Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors
por: Li, Daoqun, et al.
Publicado: (2021)

In silico analysis of SARS-CoV-2 papain-like protease potential inhibitors
por: Elseginy, Samia A., et al.
Publicado: (2021)

Deubiquitinating Activity of the SARS-CoV Papain-Like Protease
por: Barretto, Naina, et al.
Publicado: (2006)

Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
por: Kulandaisamy, Rajkumar, et al.
Publicado: (2022)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors
por: Kim, Hoshin, et al.
Publicado: (2022)

Synthesis of the Novel Covalent Cysteine Proteases Inhibitor with Iodoacetic Functional Group
por: Hartman, Kinga, et al.
Publicado: (2020)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
por: Zain, Rula, et al.
Publicado: (2021)

SARS-CoV-2 Papain-Like Protease Potential Inhibitors—In Silico Quantitative Assessment
por: Stasiulewicz, Adam, et al.
Publicado: (2021)

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2
por: Shan, Hengyue, et al.
Publicado: (2021)

Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease
por: Li, Lingyu, et al.
Publicado: (2022)

High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
por: Zang, Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_krsds18qdvdlqebgs34dmjj9rg